Bioterrorism: Our Frontline Response, Evaluating US Public Health and Medical Readiness
Item Details
Title
Bioterrorism: Our Frontline Response, Evaluating US Public Health and Medical Readiness
Topics
This hearing before the Subcommittee on Public Health examines topics related to US bioterrorism preparedness, such as the national pharmaceutical stockpile, deterrence, outbreak containment, and research and development.
Date
1999
Conclusions
We are more vulnerable to bioterrorism than any other type of warfare. We do not have the public health or pharmaceutical capacity to respond to an attack effectively. Further investment in detection, development of countermeasures, public health, and interagency communication will better prepare us to respond to a biological threat no matter its origin. Anthrax and smallpox are the most concerning due to high case fatality rate and lack of immunity in the population.
Files
Source
United States Senate Subcommittee on Public Health Preparedness of the Committee on Health, Education, Labor, and Pensions. Bioterrorism: Our Frontline Response, Evaluating US Public Health and Medical Readiness, Hearing Before the Subcommittee on Public Health of the Committee on Health, Education, Labor, and Pensions. US Government Printing Office. 1999.
Citation
“Bioterrorism: Our Frontline Response, Evaluating US Public Health and Medical Readiness,” Collection of Biothreat Risk Assessments (COBRA), accessed October 16, 2024, https://cobrabiosecurity.org/items/show/463.